Gut microbiome affects the response to immunotherapy in non ‐small cell lung cancer
ConclusionThe findings of the present study indicated that the diversity of gut microbiota and SCFAs is related to the efficacy of immunotherapy. FMT can effectively delay tumor progression, and enhance the effect of immunotherapy, thus providing evidence for improving the efficacy of immunotherapy in NSCLC patients.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Shengnan Ren,
Lingxin Feng,
Haoran Liu,
Yuke Mao,
Zhuang Yu Tags: ORIGINAL ARTICLE Source Type: research
More News: Acetic Acid | Cancer | Cancer & Oncology | Immunotherapy | Lung Cancer | Lung Transplant | Non-Small Cell Lung Cancer | Study | Transplants